Skip to main content

Table 6 Vaccination and treatment costs

From: Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting

 

DRG-code

Unit prices, EUR

Sources

Vaccination costs

PCV20

-

77.08

[14]

PPV23

-

26.62

[14]

Administration costs

-

46.96

[5]

Treatment costs

Bacteraemia

416 N

11,454.45

[43]

Meningitis

20

12,386.31

[43]

Pneumonia with hospital contact (At risk and High risk)

89

5,909.44

[43]

Pneumonia with hospital contact (Low risk)

90

4,133.38

[43]

Pneumonia without hospital contact

-

45.32

[5, 44]

  1. Note: Overview of the costs included in the model. DRG: diagnosis-related groups; PCV20: 20-valent pneumococcal conjugate vaccine; PPV23: 23-valent pneumococcal polysaccharide vaccine